A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
Status:
Completed
Trial end date:
2020-01-09
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared
to placebo, in lowering fasting TG levels in subjects with fasting TG levels ≥500 mg/dL and
≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L) after 12 weeks of treatment.
Approximately 615 subjects will be screened to obtain 245 randomized subjects following a
treatment allocation ratio of 2.5:1 (CaPre:placebo).